[1] 陈浩, 王永庆, 孟玲, 等. 凝血因子Xa抑制剂研究进展[J]. 药学与临床研究, 2013, 21(6):655-659. [2] Perzborn E, Roehrig S, Straub A, et al. Rivaroxaban: a new oral factor Xa inhibitor[J]. Arterioscler Thromb Vasc Biol, 2010, 30(3):376-381. [3] Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity 1[J]. J Clin Pharmacol, 2007, 47(11):1398-1407. [4] Buller HR, Prins MH, Lensin AW. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J]. N Engl J Med, 2012, 366(14):1287. [5] Mega JL, Braunwald E, Wiviott S D, et al. Rivaroxaban in patients with a recent acute coronary syndrome[J]. N Engl J Med, 2012, 366(1):9-19. [6] Mega JL, Braunwald E, Wiviott S D, et al. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome[J].Am J Cardiol, 2013, 112(4):472-478. [7] Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism.[J]. N Engl J Med, 2010, 363(26):2499. [8] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med,2011, 365(10):883-891. [9] 李超, 郭锦材, 张拥军, 等. 利伐沙班合成路线图解[J]. 中国医药工业杂志, 2012, 43(12):1046-1048. [10] 李杰, 潘辛梅, 赖永莉. 利伐沙班的合成研究进展[J]. 山东化工, 2018, 47(6):48-53. [11] M·贝尔维, C·托马斯, J·雷泽,等. 制备方法[P]. 德国,CN1906191,2007-01-31. |